T003 HHSN2610003 Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers - Task Order 2015 E-07 - Evaluation of the Cancer Prevention Efficacy of GLG-302

Grant

Date/time Interval

  • September 15, 2015 - September 16, 2021
  • Total Award Amount

  • 577292.00
  • Direct Costs

  • 392716.00
  • Sponsor Award Id

  • HHSN261201500036I-HHSN2610003
  • Contributor

  • Grubbs Ph.D., Clinton   Principal Investigator  
  • Juliana, M   Investigator